🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

Recruitingn/aAges 18 Years - 65 YearsAllInstitut de Recerca Biomèdica de Lleida
NCT06226194 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results. The general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrate

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Men and women between the ages of 18 and 65 at the time of surgery * SG or RYBP as bariatric procedure. * With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI\>40.0 kg/m2 at the time of surgery. * Provision of an informed consent form signed and personally dated by the patient. * With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities). Exclusion Criteria: * Any previous gastrointestinal surgery * Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS * End stage kidney disease (eGFR \<15 ml/min/1.73m2) or liver cirrhosis at baseline * Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer) * Known type 1 diabetes or LADA diabetes * Women who become pregnant during the follow-up period * Current drug or alcohol abuse * Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.
💊

What it tests

  • Not listed
📍

Where

1 site
IRBLleida
Lleida, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy